| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Alnylam Pharmaceuticals is at the forefront of innovation in siRNA therapeutics, marking significant advancements in biotechnology aimed at delivering effective treatments. The focus on siRNA technology highlights the company's commitment to pioneering drug development, which is driving growth and improving patient outcomes. Nevertheless, the complexity of siRNA drug development and regulatory challenges may pose risks to timely market entry and widespread adoption. |
| The price action of Alnylam Pharmaceuticals (ALNY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.7 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for ALNY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.9, and the negative at -0.2 on 2025-03-28. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (5.3) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| ALNY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-28 | 0%(0%) | 0 | 0% | 0.7 | 5.3 | -1 | |||||||
| 2025-03-27 | 0%(0%) | 0 | 0% | 0.7 | 4.9 | -1 | |||||||
| 2025-03-26 | 0%(0%) | 0 | 0% | 0.7 | 4.9 | -1 | |||||||
| 2025-03-25 | 0%(0%) | 0 | 0% | 0.7 | 4.9 | -1 | |||||||
| 2025-03-24 | 0%(0%) | 0 | 0% | 0.7 | 4.9 | -1 | |||||||
| 2025-03-21 | 0%(0%) | 0 | 0% | 0.7 | 5.2 | -1 | |||||||
| 2025-03-18 | 0%(0%) | 0 | 0% | 0.7 | 5.2 | -1 | |||||||
| 2025-03-17 | 0%(0%) | 0 | 0% | 0.7 | 5.2 | -1 | |||||||
| 2025-03-14 | 0%(0%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-03-13 | 0%(0%) | 0 | 0% | 0.6 | 4.3 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-09-29 03:57:50 The significant investments reported in the siRNA gene silencing market signal strong interest and confidence in the therapeutic innovation potential, indicating future financial opportunities. |
| 2025-09-29 03:57:50 Alnylam Pharmaceuticals leads in conducting numerous clinical trials, positioning itself as a key player and leader in the RNAi therapeutic research space. |
| 2025-09-29 03:57:50 The report indicates a growing market landscape for siRNA gene silencing, with significant mergers and acquisitions indicating robust industry activity and potential growth. |
| 2025-09-29 03:57:50 The advancement of siRNA therapeutics, highlighted by Alnylam Pharmaceuticals' developments, showcases the innovative strides being made in biotechnology for effective treatments. |
| 2025-09-29 03:57:50 The FDA's approval of Qfitlia⢠(fitusiran) marks a significant milestone in the regulatory landscape for RNAi therapeutics, demonstrating successful compliance and advancement in the treatment of hemophilia. |